 Thomas Jensen
Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liraglutide | 3 | 2020 | 27 | 0.460 |
Why?
| | Atrial Premature Complexes | 2 | 2004 | 3 | 0.450 |
Why?
| | Atrial Fibrillation | 2 | 2004 | 325 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2087 | 0.290 |
Why?
| | Glucagon-Like Peptides | 2 | 2023 | 22 | 0.270 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 3 | 2013 | 172 | 0.240 |
Why?
| | Tachycardia, Paroxysmal | 1 | 2003 | 7 | 0.220 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 246 | 0.210 |
Why?
| | Body Composition | 3 | 2013 | 590 | 0.210 |
Why?
| | Cardiovascular Diseases | 3 | 2023 | 1726 | 0.200 |
Why?
| | Quality of Life | 3 | 2023 | 2346 | 0.190 |
Why?
| | Receptors, Vasopressin | 1 | 2021 | 18 | 0.180 |
Why?
| | Vasopressins | 1 | 2021 | 56 | 0.180 |
Why?
| | Fructose | 1 | 2021 | 100 | 0.170 |
Why?
| | Hypoglycemic Agents | 4 | 2023 | 1011 | 0.160 |
Why?
| | Cardiovascular System | 1 | 2020 | 126 | 0.160 |
Why?
| | Weight Loss | 3 | 2013 | 642 | 0.150 |
Why?
| | Metabolic Syndrome | 1 | 2021 | 320 | 0.140 |
Why?
| | Obesity | 4 | 2023 | 2505 | 0.140 |
Why?
| | Metformin | 1 | 2020 | 274 | 0.140 |
Why?
| | Aldehyde Reductase | 1 | 1996 | 24 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 180 | 0.120 |
Why?
| | Naltrexone | 1 | 2015 | 82 | 0.110 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2004 | 53 | 0.110 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 135 | 0.110 |
Why?
| | Anti-Obesity Agents | 2 | 2009 | 45 | 0.100 |
Why?
| | Double-Blind Method | 5 | 2018 | 1656 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2016 | 3254 | 0.100 |
Why?
| | Heart Failure | 1 | 2023 | 1958 | 0.090 |
Why?
| | Aged | 9 | 2020 | 18973 | 0.090 |
Why?
| | Factor VIII | 1 | 2010 | 52 | 0.090 |
Why?
| | Alcoholism | 1 | 2015 | 710 | 0.080 |
Why?
| | Male | 13 | 2021 | 55420 | 0.070 |
Why?
| | Middle Aged | 9 | 2020 | 26621 | 0.070 |
Why?
| | Hyperlipidemias | 2 | 2000 | 121 | 0.070 |
Why?
| | Adult | 10 | 2020 | 30395 | 0.070 |
Why?
| | Humans | 19 | 2023 | 114080 | 0.060 |
Why?
| | Anticoagulants | 1 | 2010 | 547 | 0.060 |
Why?
| | Prevalence | 2 | 2020 | 2249 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 949 | 0.060 |
Why?
| | Bundle-Branch Block | 1 | 2005 | 28 | 0.060 |
Why?
| | Ventricular Fibrillation | 1 | 2005 | 51 | 0.060 |
Why?
| | Systole | 1 | 2005 | 176 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2089 | 0.060 |
Why?
| | Female | 11 | 2020 | 59349 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1257 | 0.060 |
Why?
| | Catheter Ablation | 2 | 2005 | 287 | 0.060 |
Why?
| | Tachycardia, Ventricular | 1 | 2005 | 153 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 94 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1205 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 384 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2020 | 9051 | 0.050 |
Why?
| | Cytochrome c Group | 1 | 2002 | 35 | 0.050 |
Why?
| | Pseudomonas | 1 | 2002 | 26 | 0.050 |
Why?
| | Fructokinases | 1 | 2021 | 29 | 0.050 |
Why?
| | Drinking | 1 | 2021 | 33 | 0.050 |
Why?
| | Hep G2 Cells | 1 | 2021 | 59 | 0.050 |
Why?
| | Stroke Volume | 1 | 2023 | 513 | 0.050 |
Why?
| | Arteriosclerosis | 2 | 1997 | 82 | 0.040 |
Why?
| | Placebos | 1 | 2018 | 197 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2018 | 6307 | 0.030 |
Why?
| | Young Adult | 4 | 2016 | 10459 | 0.030 |
Why?
| | Prospective Studies | 2 | 2005 | 6198 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3007 | 0.030 |
Why?
| | Albuminuria | 1 | 1997 | 164 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 134 | 0.030 |
Why?
| | Denmark | 3 | 2008 | 39 | 0.030 |
Why?
| | Diabetic Neuropathies | 1 | 1996 | 78 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 3315 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 82 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2563 | 0.030 |
Why?
| | Adolescent | 5 | 2016 | 17811 | 0.030 |
Why?
| | Hyperlipidemia, Familial Combined | 1 | 1993 | 3 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2465 | 0.030 |
Why?
| | Liver | 1 | 2021 | 1633 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4392 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4682 | 0.020 |
Why?
| | Hospitalization | 1 | 2020 | 1763 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 3499 | 0.020 |
Why?
| | Risk Factors | 3 | 2018 | 8612 | 0.020 |
Why?
| | Chemistry, Clinical | 1 | 1990 | 11 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 2010 | 102 | 0.020 |
Why?
| | Half-Life | 1 | 2010 | 141 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 273 | 0.020 |
Why?
| | Lipoproteins | 1 | 1990 | 159 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2015 | 655 | 0.020 |
Why?
| | Caloric Restriction | 1 | 2008 | 89 | 0.020 |
Why?
| | Insulin | 1 | 2016 | 2080 | 0.020 |
Why?
| | Lipids | 1 | 1990 | 564 | 0.020 |
Why?
| | Hemorrhage | 1 | 2010 | 600 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1837 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 660 | 0.020 |
Why?
| | Mice | 1 | 2021 | 14847 | 0.010 |
Why?
| | Syndrome | 1 | 2005 | 330 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 12521 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 1830 | 0.010 |
Why?
| | Radiography | 1 | 2005 | 803 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 561 | 0.010 |
Why?
| | Guanidine | 1 | 2002 | 18 | 0.010 |
Why?
| | Calorimetry, Differential Scanning | 1 | 2002 | 34 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2002 | 47 | 0.010 |
Why?
| | Protein Denaturation | 1 | 2002 | 68 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2002 | 135 | 0.010 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2000 | 27 | 0.010 |
Why?
| | Protein Folding | 1 | 2002 | 239 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2000 | 86 | 0.010 |
Why?
| | Animals | 1 | 2021 | 31570 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 796 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6077 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1547 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1368 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2000 | 1381 | 0.010 |
Why?
| | Reference Values | 1 | 1990 | 739 | 0.000 |
Why?
| | Cohort Studies | 1 | 1997 | 4885 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1993 | 5039 | 0.000 |
Why?
| | Infant | 1 | 1993 | 7946 | 0.000 |
Why?
| | Child, Preschool | 1 | 1993 | 9121 | 0.000 |
Why?
| | Child | 1 | 1993 | 18408 | 0.000 |
Why?
|
|
Jensen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|